|
|
News Breaks
|
December 15, 2011
|
| 09:02 EDT |  | CORT |
| theflyonthewall.com: | FDA will not require risk evaluation in Corcept's distribution of Korlym | | Corcept Therapeutics announced that it has been advised by the U.S. Food and Drug Administration that no Risk Evaluation and Mitigation Strategy will be required in connection with Corcept's proposed distribution of its lead product candidate, mifepristone, to which Corcept has given the brand name Korlym. The FDA is currently reviewing Corcept's New Drug Application for Korlym, a glucocorticoid receptor type II antagonist that blocks the cortisol receptor, for the treatment of the clinical and metabolic effects of hypercortisolism in patients with endogenous Cushing's Syndrome. The FDA's decision with respect to REMS does not alter the Prescription Drug User Fee Act date for completion of FDA review, which remains February 17, 2012. :theflyonthewall.com |
|
|
News For CORT From The Last 14 Days Check below for free stories on CORT the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 24, 2012
|
| 17:22 EDT |  | CORT |
|
|
|
|
|
Subscribe for More Information